Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Unresponsive NMIBC with CIS

Wassim Kassouf, MD,[1*] Sarah P. Psutka, MD, MSc,[2] Sima P. Porten, MD, MPH,[3] Kristen R. Scarpato, MD, MPH,[4] Mary E. Westerman, MD [5] Anne K. Schuckman, MD, MPH [6]

[1] McGill University Health Center, Montreal, QC, Canada, [2] University of Washington, Seattle, Washington, USA [3] University of California, San Francisco, California, USA [4] Vanderbilt University Medical Center, Nashville, Tennessee, [5] University of North Carolina, Raleigh, North Carolina, USA, [6] USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA

BACKGROUND

- **Cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action: it selectively replicates in and lyses cancer cells while amplifying the immune response against bladder tumors**
- **Updated BOND-003 results presented at AUA 2025 show a 75% CR and median DoR of 27.9 months, with 0% ≥ Grade 3 TRAEs—consistent with previous findings [1-5]**
- **Granted US FDA Fast Track and Breakthrough Therapy Designations in HR BCG-UR NMIBC CIS +/- Ta/T1**
- **An Expanded Access Program (EAP) is a pathway designed to give patients access to potentially beneficial investigational treatments before they are approved[6]**

CRETO-EAP will offer cretostimogene for patients with CIS-containing BCG-unresponsive NMIBC, with the following considerations:

- Ineligible for, or have limited access to, other BCG-UR CIS clinical trials
- Are unable to tolerate available treatment options
- Have limited or restricted access to alternative therapies

References: 1 Burke, J Urol; 2012, **2** Packiam, Uro Onc; 2018, **3** Li, AUA Meeting; 2022, **4** Li, *Nat Med*; 2024, **5** Tyson, AUA Meeting, 2025; **6** U.S. FDA. Expanded Access

Acknowledgements: Andy Darilek, MD, Jee-Hyun Kim, PhD, John McAdory, Kara Sabourin, Kristen Scholz, DHSc, Kyle Rice, Michael Lambert, Pradnya Gunjotikar, Rebecca Tregunna, MD, MBA, Shelja Patel, PharmD, Vijay Kasturi, MD

CRETO-EAP
EXPANDED ACCESS PROGRAM

Actively Enrolling
Real-World Population
Diverse Patients and Sites

Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action



STUDY DESIGN



- **Flexible entry criteria: ECOG 0-3, expanded window for prior intravesical BCG, previous investigational therapy permitted, adaptable screening process**
- **Eligibility and efficacy based on local assessments**
- **Co-primary endpoints: Safety & CR at any time**
- **Secondary endpoints: DoR, PFS, CFS, PROs and HRQoL**

Study Administration Schedule

	Induction	Optional Re-Induction	Maintenance/Follow-Up						
Month	0	3	6	9	12	15	18	21	24
Instillation	1 2 3 4 5 6	1 2 3 (4 5 6)	1 2 3	1 2 3	1 2 3		1 2 3		1 2 3

x6 for Non-Responder

- **Partial responders (Mo 6 & beyond) may receive continued treatment at the discretion of the Investigator**
- **Streamlined post instillation direct close contact instructions**
- **Patients will be assessed for response during routine NMIBC surveillance, according to AUA guidelines**

Canadian patients may be eligible through Health Canada's Special Access Program
For details, please contact:
CRETO.EAP@cgoncology.com

Disclosures: Dr. Kassouf received advisory board honoraria from CG Oncology

Contact Information: Wassim Kassouf, MD;
Wassim.Kassouf.med@ssss.gouv.qc.ca